Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02554877 | A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin | PHASE2 | COMPLETED | 206 | — | — | Oct 1, 2015 | Aug 1, 2016 | Aug 7, 2017 | 38 | United States, Canada |
HbA1c was a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Baseline was defined as the last pre-dose measurement prior to first double blind dosing for the study.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| PF-06291874, 30 mg | EXPERIMENTAL | - |
| PF-06291874, 60 mg | EXPERIMENTAL | - |
| PF-06291874, 100 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06291874 | DRUG | study drug to be given as an oral tablet at 30, 60 or 100 mg |
| Placebo | DRUG | oral tablet |
Inclusion Criteria: 1. Males or non-childbearing potential females between the ages of 18 (or the minimum country specific age of consent if \>18) and 70 years, inclusive, at the screening visit (V1) with the diagnosis of T2DM;Female subjects who are not of childbearing potential 2. Subjects who ha...